Equities

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS

ECILC.E:IST

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TRY)42.94
  • Today's Change0.22 / 0.51%
  • Shares traded1.15m
  • 1 Year change-8.17%
  • Beta0.9031
Data delayed at least 15 minutes, as of Nov 15 2024 10:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS, formerly known as Eczacibasi Ilac Sanayi ve Ticaret A.S., (EIS) is a Turkey-based company active in the pharmaceutical industry through its subsidiaries, affiliates and joint ventures. Its product portfolio consists of drugs for human health, veterinary drugs and personal care products, such as body and facial creams, hair gels, deodorants and various other products. The Company is also engaged in real estate development and construction through its subsidiary, Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., formerly known as Eczacibasi Insaat ve Ticaret A.S. Its subsidiaries also include Eczacibasi Ilac Ticaret A.S. (EIT), EHP Eczacibasi Health Care Products Joint Stock Co. (EHP), and Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., among others. EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a member of Eczacibasi Group of Companies.

  • Revenue in TRY (TTM)9.15bn
  • Net income in TRY3.60bn
  • Incorporated1951
  • Employees1.10k
  • Location
    EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret ASBuyukdere Cad. Ali Kaya Sok. No:5 LeventISTANBUL 34394TurkeyTUR
  • Phone+90 2 123508000
  • Fax+90 2 123717399
  • Websitehttps://www.eis.com.tr
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tong Ren Tang Technologies Co Ltd32.68bn3.09bn28.82bn4.01k9.320.85484.660.88190.54720.54725.785.970.50260.98815.221,806,024.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Torii Pharmaceutical Co Ltd12.93bn1.16bn28.83bn583.0024.271.0723.032.23187.71187.712,093.334,271.840.44112.742.30100,924,500.003.966.524.397.3544.4649.558.9717.985.19--0.0024.1711.74-2.674.4428.76-20.3820.11
Liquidia Corp509.55m-3.85bn28.91bn136.00--12.21--56.74-1.57-1.570.21020.82080.0993--4.04109,117.60-75.00-55.02-87.85-62.6969.5282.18-755.46-474.595.78-29.470.578--9.7545.23-91.40--66.93--
Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS12.60bn178.31m29.15bn617.00163.454.9551.412.310.59440.594442.0019.621.6815.729.7820,256,010.002.3112.393.7317.5319.3119.061.376.951.293.410.1773---23.3847.18-28.97147.97----
Sihuan Pharmaceutical Holdings Group Ltd8.34bn-179.62m29.20bn2.65k--1.39--3.50-0.0044-0.00440.20360.51090.15060.8943.90657,933.40-1.77-6.85-2.68-9.1065.9175.81-11.78-36.231.50--0.181---14.70-8.6097.23--0.9325--
EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr9.15bn3.60bn29.27bn1.10k8.130.61776.583.205.255.2513.3669.160.22274.127.887,999,978.008.768.499.499.0633.5532.9439.3258.231.22--0.0698--86.9456.41-8.1662.73141.5931.51
Chengdu Easton Biopharmaceuticals Co Ltd6.21bn1.19bn29.40bn1.40k24.572.31--4.741.431.437.4715.160.39411.836.97933,769.907.538.729.2310.6475.7685.1019.1119.162.65--0.071726.80-4.567.76-8.0910.9117.99--
Beijing Tong Ren Tang Chinese Medicine6.07bn2.18bn29.55bn779.0013.551.7610.834.860.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
Orchid Pharma Ltd3.68bn485.97m29.70bn872.0060.125.9747.698.0723.9623.96181.23241.380.57871.964.4910,376,120.007.57-0.97349.09-1.4041.2640.7413.09-2.401.826.740.1187--23.056.4373.595.8457.79--
Tchaikapharma High Quality Medicines AD917.41m35.62m29.87bn201.00817.4614.99365.3732.560.02150.02150.57491.170.40352.500.8022259,832.501.571.831.772.1231.7631.283.885.144.6222.230.0855--12.524.9921.79-21.22----
Data as of Nov 15 2024. Currency figures normalised to EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's reporting currency: Turkish Lira TRY

Institutional shareholders

1.65%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 02 Oct 20245.71m0.83%
Dimensional Fund Advisors LPas of 31 Jul 20242.34m0.34%
Goldman Sachs Asset Management LPas of 03 Oct 2024891.34k0.13%
BlackRock Advisors (UK) Ltd.as of 03 Oct 2024565.81k0.08%
JPMorgan Investment Management, Inc.as of 03 Oct 2024423.56k0.06%
BlackRock Fund Advisorsas of 03 Oct 2024376.91k0.06%
State Street Global Advisors Ltd.as of 02 Oct 2024292.58k0.04%
BlackRock Investment Management (UK) Ltd.as of 30 Sep 2024275.58k0.04%
Charles Schwab Investment Management, Inc.as of 03 Oct 2024222.90k0.03%
SSgA Funds Management, Inc.as of 03 Oct 2024216.24k0.03%
More ▼
Data from 30 Jun 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.